Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody: balugrastim, lenograstim, lipegfilgrastim +7 | 0.45 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 1 stopped | 0.84 |
| literature PubMed | 4 Parkinson's papers of 530 | 0.79 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2539
Sealed predictions
- CSF3R in dopamine neurons, braak-0.39 (p 0.303) → -0.48 (p 0.186)receipt 2546
Swarm cases
receipt 2546: CSF3R in dopamine neurons, braak
- power
- full sample -0.52 (p 0.027, n 18), 95% CI -0.79 to -0.07. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.52 (p 0.027, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.61 (p 0.0075, n 18). not the mix.
- skeptic
- leave-one-out range -0.69 to -0.45, sign flips 0; without severely affected donors -0.52 (p 0.027, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CSF3R in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts